Dapagliflozin Beneficial for Heart Failure, Regardless of Frailty
Risk reduced for worsening heart failure or cardiovascular death, regardless of frailty index class
Heart Failure
Accupril Tablets Recalled Due to Nitrosamine Impurity
Nitrosamine impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time.
RAASi Dose Reduction, Discontinuation in CKD Common After Hyperkalemia
In a study of patients with CKD and/or heart failure on RAASi therapy, the proportion of patients who received dose reductions or had therapy discontinued after new-onset hyperkalemia increased with hyperkalemia severity.
Recommendations Updated for Management of Heart Failure
Sodium-glucose cotransporter-2 inhibitors recommended for HF with reduced, mildly reduced ejection fraction
Serum Sodium in Upper Part of Normal Range Linked to Heart Failure
Serum sodium above 143 mmol/L linked to increased odds of left ventricular hypertrophy, heart failure
February 2022 Recap: Drug Pipeline Updates
A review of regulatory and drug development status updates.
Clinical Benefit Seen With In-Hospital Initiation of Empagliflozin in Heart Failure Patients
Findings showed that patients treated with empagliflozin were 36% more likely to experience a clinical benefit.
Mavacamten Evaluated in Patients With Obstructive Hypertrophic Cardiomyopathy Eligible for SRT
The VALOR-HCM trial evaluated the effects of mavacamten in over 100 patients with symptomatic obstructive HCM (NYHA class III-IV) who met the guideline criteria for SRT and had been referred for an invasive procedure.
MPR Weekly Dose Podcast Episode 107
This week: millions of courses of a COVID-19 oral antiviral was provided to the US government for distribution throughout the country; There’s a draft guidance for novel nonopioid analgesics; Possible strangulation warning for enteral feeding tubes; A new treatment has been approved for cold agglutinin disease; And a treatment is under review for HFrEF.
Omecamtiv Mecarbil Under Review for Heart Failure With Reduced Ejection Fraction
The NDA is supported by data from the phase 3 GALACTIC-HF trial which included 8256 adults with heart failure with reduced ejection fraction,
